Natco Pharma Limited receives EIR for Vizag formulation facility

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced successful closure of inspection and receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India, for an inspection conducted during the period from 24th March to 30th March, 2020.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.603.3 as compared to the previous close of Rs. 601.05. The total number of shares traded during the day was 12237 in over 956 trades.

The stock hit an intraday high of Rs. 610.05 and intraday low of 596.75. The net turnover during the day was Rs. 7378209.

Source : Equity Bulls

Keywords